Solutions: Extend trial to 6 months before concluding inefficacy (some benefits take longer), increase dosing within safe ranges if using lower end, switch peptides (try Cerebrolysin if using BPC-157, or vice versa), add comprehensive eye exam to rule out progression versus peptide failure, consider peptides preventing worsening rather than producing improvement, discontinue if truly no benefit after 6 months rigorous trial
Furthermore, the residue could contribute to the stabilization of the thiolate of the catalytic cysteine as reported for human Grx1 (ref
Tesamorelin Side Effects Thinking about starting tesamorelin or already using it
A Phase 1 clinical trial of the MOTS-C analog CB4211 found the compound safe after 7 days of dosing, though persistent mild injection site bumps were noted
The SE group was exposed to two cigarettes (Winfield Red, 1.2 mg nicotine